+62.4%
EWY vs MRNA
+945.0%
-882.6%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +13.1% | -15.0% | -2.4% |
| 7D | -8.3% | +20.6% | -29.0% | -9.1% |
| 30D | -20.5% | +27.1% | -47.7% | -21.4% |
| 3M | -11.1% | +353.4% | -364.5% | -20.5% |
| 6M | -7.0% | +446.3% | -453.3% | -21.8% |
| YTD | +56.5% | +776.2% | -719.7% | +26.1% |
| 1Y | +62.4% | +987.9% | -925.5% | +25.7% |
| All | +62.4% | +945.0% | -882.6% | +25.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling